The Effect of Intravenous EACA on Blood Loss and Transfusion Requirements After Bilateral VRO
Status:
Completed
Trial end date:
2020-10-26
Target enrollment:
Participant gender:
Summary
E-Aminocaproic acid (EACA) is an anti-fibrinolytic agent that is used to decrease blood loss
and transfusion requirements after several orthopedic procedures. The aim of this prospective
double-blind placebo-controlled randomized trial is to determine whether IV EACA reduces
intra-operative calculated total blood loss in patients undergoing bilateral varus rotational
osteotomy (VRO). This study will also investigate intraoperative cell saver utilization,
transfusion of allogeneic blood, hospital length-of-stay (LOS), short term complications, and
long-term outcomes.This study will provide Level I evidence and has the potential to improve
outcomes in children undergoing this procedure.